Munich, Germany, March 30, 2021

Funding will advance Ethris’ development of an mRNA-based therapeutic to treat SARS-CoV-2 and its variants

Zurich, Switzerland and Munich, Germany, April 1, 2020

Neurimmune AG and Ethris GmbH announced today an exclusive partnership to develop mRNA-encoded, neutralizing anti-SARS-CoV-2 antibodies administered by inhalation for the treatment of Covid-19.

October 1, 2019

Ethris’ existing collaboration with the Munster University Hospital has been awarded a research grant by the Central Innovation Program for SMEs (ZIM). The funding will help accelerate the joint research project in primary ciliary dyskinesia (PCD), including evaluation of ETH42, a first-in-class SNIM®RNA product in preclinical development.

June 3, 2019

Ethris announced  the expansion of the company’s leadership team by the addition of Thomas Langenickel, M.D. in the role of Chief Medical Officer. Dr. Langenickel joined Ethris from Novartis AG, where he was Executive Director and Head of Respiratory Profiling within the Translational Medicine Group.

December 07, 2018

Ethris adapted the responsibilities among its leadership team to position the company for the next phase of its development. As a result, Dr. Gita Dittmar took on the role as Chief Executive Officer, PD Dr. Carsten Rudolph became Chief Scientific Officer and Prof. Dr. Christian Plank became Chief Technology Officer.

August 21, 2017

Ethris  and AstraZeneca signed a five-year strategic research collaboration that is focused on developing new stabilized non-immunogenic modified RNA therapies for respiratory diseases using Ethris’ proprietary SNIM®RNA technology. Ethris received €25 million upfront plus research funding and is eligible for future research and development milestones, including sales related royalties upon commercialization.

July 19, 2016

Ethris announced the addition of Dr. Leon Chen, Dr. Thomas Chalberg, and Justin Duckworth to the Ethris Board of Directors to support the next stage of the company’s development.